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We have constructed virus-like particles (VLPs) harboring hemagglutinin (HA), neuraminidase (NA), matrix protein 1 (M1) ,and
proton channel protein (M2) using baculovirus as a vector in the SF9 insect cell. The size of the expressed VLP was estimated
to be ∼100nm by light scattering experiment and transmission electron microscopy. Recognition of HA on the VLP surface by
the HA2-speciﬁc monoclonal antibody IIF4 at acidic pH, as probed by surface plasmon resonance, indicated the pH-induced
structural rearrangement of HA. Uptake of the particle by A549 mediated by HA-sialylose receptor interaction was visualized by
the ﬂuorescent-labeled VLP. The HA-promoted cell-virus fusion activity was illustrated by ﬂuorescence imaging on the Jurkat
cells incubated with rhodamine-loaded VLP performed at fusogenic pH. Furthermore, the green ﬂuorescence protein (GFP) was
fused to NA to produce VLP with a pH-sensitive probe, expanding the use of VLP as an antigen carrier and a tool for viral
tracking.
1.Introduction
Virus-like particle (VLP) has been extensively studied for its
vaccine capacity in the last 20years. More than a dozen of
VLP-based vaccines have been tested in clinical trials. Two of
them against hepatitis B and human papilloma viruses are
commercially available as prophylactics [1]. The merits of
VLP-based vaccine rest on its viral mimicry and devoid of
genetic materials, hence alleviating the safety concerns [2].
The repetitive and ordered structures of VLPs are conducive
to opsonization, resulting in enhanced phagocytosis [3, 4],
and are capable to activate B cells in a T cell-independent
manner [5, 6]. Owing to the virus-like dimension and
particulate nature, VLPs are easily taken up by antigen-
presenting cells (APCs) [7, 8]a n dm o r ee ﬃcient in cross-
presentation of antigens to MHC I molecules compared to
the soluble antigen and hence the possibility of activating
antigen-speciﬁc cytotoxic T lymphocytes (CTLs) [9].
Although the VLP-based vaccines have the potential to
induce CTL response, most of them favor the production
of humoral immunity but poorly evoke CTL response
if additional stimuli for innate immune system and, in
particular, APC were neglected [1]. It is somewhat surprising
that VLPs derived from baculovirus system incorporating
viral structural proteins of inﬂuenza virus were found to
induce both cell-mediated and humoral immunity to confer
full protection from viral challenge [10–12]. This distinct
feature drew our attention on the interaction between VLPs
and cells since most of the VLP-based strategies for vaccine
development do not involve antigens with functions of
ligand binding and membrane fusion in contrast with the
hemagglutinin of inﬂuenza VLP.
Inﬂuenza A virus is an enveloped RNA virus with
three transmembrane proteins: hemagglutinin (HA), neu-
raminidase (NA), and ion channel protein (M2) along with
matrix protein 1 (M1) underlying the viral envelope. The
major tasks of these proteins include ligand binding and
membranefusionforHA[13,14],spreadingofviralprogeny
and facilitating entry of the virus for NA [15–17], proton
transfer for viral uncoating as well as assembly and budding2 Journal of Biomedicine and Biotechnology
Table 1: Primer sequence used in pFastbac Dual vector construc-
tion.
Primer Sequence 5
 –3
 
HA forward GATCCGCCACCATGAAATTCTTAGTCAACG-
TTGCCC
HA reverse GCGGCCGCCCGTCTTCCATCTTCTTGTTTA-
AATTCT
NA forward CTCGAGGCCACCATGAATCCAAACCAG-
AAAATAAT
NA reverse GGTACCCTACTTGTCAATGGTGAACG
M1 forward CTCGAGGCCACCATGAGTCTTCTAACC-
GAGGTC
M1 reverse GGTACCTCACTTGAATCGTTGCATCTG
M2 forward GAATCCGCCACCATGAGTCTTCTAACCGAG-
GT
M2 reverse AAGCTTTTACTCCAGCTCTATGTTGA
NA-EGFP
forward-1
CTCGAGGCCACCATGAATCCAAACCAG-
AAAATAATA
NA-EGFP
forward-2
CATTACCTATAAAGTTGTTGCTGGGGTGAG-
CAAGGGCGAGGAG
NA-EGFP
reverse-1
TGAACAGCTCCTCGCCCTTGCTCACCCCAG-
CAACAACTTTATAGGT
NA-EGFP
reverse-2 GGTACCCTATTACTTGTACAGCTCGTC
ofthevirusforM2[18–20],recruitmentofviralcomponents
to the assembly site, and a major driving force for viral
budding for M1 [21, 22].
Several laboratories have produced insect cell-derived
VLPs encompassing the above-mentioned inﬂuenza proteins
for vaccine development [23]. However, there has been no
report on the characterization of the interaction between
VLPs and cells. To aﬀord a better understanding of these
interactions, we used ﬂuorescent images and dye dequench-
ing in this study in the hope of shedding some light on
the mechanism of antigen presentation, and virus-mediated
membrane fusion and its inhibition.
2.MaterialsandMethods
2.1. Plasmid Construction. HA (A/Thailand/1(KAN-1)/2004
/H5N1), NA (A/Viet Nam/1203/2004/H5N1), M1 (A/WSN/
33/H1N1) and M2 (A/WSN/33/H1N1), inﬂuenza cDNA
sequences were ampliﬁed by PCR (primer sequences were
listedintheTable 1).TheHAPCRproductswereclonedinto
BamHI/NotI site under the control of the polyhedron pro-
moter, the M1 PCR products into XhoI/KpnI site under p10
promoter of the pFastbac Dual baculovirus transfer vector
(Invitrogen), the M2 PCR products into EcoRI /HindIII site
under the polyhedron promoter, and the NA PCR products
intoXhoI/KpnI siteunderp10promoterofthepFastbacDual
baculovirus transfer vector (Invitrogen), and the NA-EGFP
PCR products into XhoI/KpnI site under p10 promoter of
the pFastbac Dual baculovirus transfer vector (Invitrogen).
All the inserted sequences were conﬁrmed by DNA sequence
analysis (Mission Biotech Inc., Taipei, Taiwan).
2.2. Generation of Recombinant Baculoviruses. Production
of recombinant baculoviruses followed the manufacturer’s
manual of Bac-to-Bac baculovirus system (Invitrogen).
Brieﬂy, the pFastbac Dual plasmids were transformed into
E.coli strain DH10Bac (Invitrogen) and selected on LB plate
containing kanamycin (Invitrogen), gentamicin (Invitro-
gen), tetracycline (Invitrogen), Bluo-gal (Invitrogen), and
IPTG (BioRad). The recombinant bacmids were con-
ﬁrmed by sequencing and then transfected into Spodoptera
frugiperda (Sf9) cells for recombinant baculovirus packaging
via the aid of Cellfectin Reagent (Invitrogen). After 4days,
the recombinant baculovirus in the supernatant was col-
lected as P1 viral stock and further ampliﬁed as P2 viral
stock for VLP puriﬁcation. The virus titer of viral stock was
determined by the end-point dilution in Sf9 cells [24].
2.3. Production and Puriﬁcation of VLP. The Sf9 insect
cells (cat. no. 11496-015, Invitrogen) were maintained as
suspension cultures in sf900 II SFM (Invitrogen) at 27◦C.
For the production of HA+ VLP, 300ml of Sf9 cells at
2 × 106cells/ml were coinfected with Dual HA, M1 and
Dual NA, M2 recombinant baculovirus at MOI of 3 and
1, respectively, whereas for the production of HA− VLP,
the Dual HA, M1 recombinant baculovirus were replaced
with M1 only recombinant baculovirus. To produce NA-
EGFP VLP, the same infection procedure was carried out
except for the replacement of Dual NA, M2 with Dual NA-
EGFP, M2 recombinant baculovirus. At 72h post-infection,
the supernatant was collected by centrifugation at 12000g
for 20min. The VLPs were precipitated at 33000 rpm
and 4◦C for 2h (RPS40ST rotor, Hitachi). The particles
were resuspended in PBS buﬀer, loaded on a 0–60% (w/v)
discontinuous sucrose gradient, and centrifuged for 4h
at 33000rpm and 4◦C (RPS40ST rotor, Hitachi). After
ultracentrifugation, fractions were collected from the top of
thegradientandanalyzedbyWesternblotting[25].Fractions
containingHA,NA,M1,andM2proteinswerecollected,and
the protein concentration was determined by BCA protein
assay kit (cat. 23225, Pierce).
2.4. Western Blotting for Detection of the Expressed Viral
Proteins. Protein samples were resolved by 12.5% SDS
polyacrylamide gel and then transferred to PVDF mem-
branes. The membrane blots were blocked with 5% nonfat
milk in Tris-buﬀered saline containing 0.1% Tween-20
and probed with primary antibodies against HA (abcam
ab21297), NA (abcam ab70759), M1 (abcam ab25918),
M2 (novus NB100-2073), separately. The presence of each
proteinwasdetectedbyHRP-conjugatedsecondaryantibody
and Enhanced Chemiluminescence (ECL) plus western blot
detection system (Amersham Bioscience). The blot images
were captured by the LAS-3000 imaging system (Fujiﬁlm,
Tokyo, Japan).
2.5. Fluorescent Dye Labeling and Fluorescence Microscopy.
The ﬂuorescent dye labeling was performed as described
previously with minor modiﬁcation [26]. VLPs suspendedJournal of Biomedicine and Biotechnology 3
in PBS were mixed with equal volume of R18- or DiO-
containing PBS to ﬁnal concentration of 10μMo fR 1 8
or DiO (Molecular probes, Invitrogen). The mixture was
incubated in dark for 1h at room temperature for R18
labelingwhileincubatedfor20minat37◦CforDiOincorpo-
ration. The R18-labeled VLPs were washed three times with
PBS, and the unincorporated dyes were ﬁltered away by a
Microcon devise with MW cutoﬀ of 50kDa. The ﬂuorecent-
labeledVLPsweremountedonaglasssupportandvisualized
by inverted ﬂuorescence microscope (Aviovert, Carl Zeiss
Inc.) with oil immersion objective (Plan-Apo 100X, N.A.
1.4). The images were processed by MetaMorph software
(Carl Zeiss Meditec, Gottingen Germany).
2.6. Dynamic Light Scattering (DLS) and Transmission Elec-
tron Microscope (TEM). T h ep a r t i c l es i z em e a s u r e m e n tw a s
executed on the miniDAWN (Wyatt Technology Corp.,
Santa Barbara, CA) equipped with a microCUVETTE and a
30mW, 685nm GaAs laser light source. One milliliter of PBS
was ﬁltrated through a 0.02μm inorganic membrane ﬁlter
(Anodisc,WhatmanInternationalLtd.,Maidstone,England)
as the DLS background. For the hydrodynamic radius (Rh)
measurement, one microliter of VLP solution was directly
mixed with the PBS and transferred in the microCUVETTE.
Data collection and analysis were performed on the ASTRA
V software (Wyatt Technology Corp., Santa Barbara, CA).
The morphology of the inﬂuenza VLP was observed by
transmissionelectronmicroscopeJEM2010(JeolLtd.,Tokyo
Japan). 3μl of diluted inﬂuenza VLPs were loaded onto
formvar-carbon-coated300-meshcoppergrids(Polysciences
Inc.) and allowed to absorb for 3minutes. The grids were
wicked dry with ﬁlter paper, rinsed once with PBS, and
negatively stained with 1% ammonium phosphotungstate
pH 7. Grids were examined by TEM at 200kV accelerating
voltage for the presence of inﬂuenza virus.
2.7. Spectroscopic Measurements. 20μl of NA-EGFP VLP
(total protein amount 15.6μg) was diluted in 50μl of PBS
with varying pH by titration with 25mM of citric acid.
The ﬂuorescent signal was recorded on a ﬂuorescence spec-
trophotometer F2500 (Hitachi). The excitation wavelength
was 470nm while emission spectra spanned 490 to 560nm.
Excitationandemissionslitwidthsweresetat2.5and10nm,
respectively.
2.8. Endocytosis of VLPs by A549 Cells. The ﬂuorescent-
labeled VLPs were diluted in ice-cold DMEM medium
containing 50mM NH4Cl and added to cover slips with
a monolayer of grown A549 cells. The maximum amount
of NH4Cl was tested for 24h for minimal cellular mor-
phological change. The cover slips were stood on ice for
1h to prevent VLP engulfed by pinocytosis. To show that
the endocytotic process is mediated by the binding between
viral HA and cellular sialylated receptors, A549 cells were
treated with neuraminidase from Vibrio cholerae (Sigma) at
4 × 10−2 unit/ml and 37◦C for 2h prior to the addition of
ﬂuorescent-labeled VLPs. After 1h incubation, the unbound
V L P sw e r ew a s h e da w a yw i t hi c e - c o l dD M E Mm e d i u m ,a n d
thecellswereculturedinDMEMmediumcontaining50mM
NH4Cl at 37◦Cf o r2 h[ 27], which was replaced with a
medium containing 5μM of DiD dye for 15min before the
cells were washed extensively with PBS and ﬁxed with 4%
paraformaldehyde in PBS at room temperature for 10min
and mounted with 50% glycerol in PBS. The R18- and
DiO-labeled VLPs taken up by A549 cells were observed
by Zeiss LSM510 META laser scanning confocal microscope
using oil immersion objective (Plan-Apo 100x, N. A. 1.4)
in multitrack channel mode. Excitation wavelengths and
emission ﬁlters were 488nm/band-pass 500–530nm for
EGFP and DiO, 561nm/band-pass 575–630nm for R18, and
561nm/band -pass 651–704nm for DiD. The images were
analyzed by LSM image browser (Zeiss).
2.9. Inhibition of VLP Binding. 5μl of R18-labeled VLPs
(protein estimation 2.4μg) were mixed with variant concen-
tration of fetuin in ﬁnal volume of 200μl and incubated
at R.T. for 5min. The mixtures were then added into
equal volume of Jurkat cells (1 × 106 cells) and incubated
at 37◦C for 10min. The cell-bound VLPs were collected
by centrifugation at 200×gf o r5 m i na n dl y s e dw i t h
octaethylene glycol dodecyl ether (C12E8, Calbiochem) in a
ﬁnal concentration of 3mM. The R18 signal was detected
by ﬂuorescence spectrophotometer F4500 (Hitachi) with
excitation at 540nm and emission at 578nm. Excitation and
emission slit widths were set at 2.5 and 10nm, respectively.
2.10. Monoclonal Antibody Binding to HA. Experiments of
surfaceplasmonresonance(SPR)wereconductedtoevaluate
the binding aﬃnity of HA2-speciﬁc mAb IIF4 to HA+ and
HA−VLP s.Inbrief,theVLPwasimmobilizedonanactivated
CM5 sensor chip, which was placed in the chamber of a
BIACORE3000biosensorsystem[28](BIAcoreAB,Uppsala,
Sweden). IIF4 used as the analyte was injected over the
CM5 sensor chip at 10μl / m i nﬂ o wr a t ea tp H7 . 4o r5 . 0
in sodium phosphate buﬀer to examine the pH-dependent
conformational change as observed for the native inﬂuenza
virus. The sensor surface was regenerated with solution of
0.1M NaCl and 0.02N NaOH. The SPR kinetic data were
ﬁtted by the BIAevaluation 3.1 software.
2.11. Immunoﬂuorescence Detection of VLP. 20μlo fV L P
was diluted in 200μl of PBS, and then added onto poly-L-
lysine-treated coverslip on ice for 2h. After PBS washing,
the pH 5 treated VLP was incubated with low pH buﬀer
(10mM HEPES, 10mM MES in PBS, pH 5.0) for 2min,
rinsed with PBS, and ﬁxed with 4% paraformaldehyde and
subsequently blocked with 10% FBS in PBS at RT for 1h.
The VLP was probed with IIF4 mAB (kindly provided by
Dr. Vareckova, 100x diluted) and subsequently hybridized
with FITC conjugated antimouse IgG (500x diluted) at 37◦C
for 1h. The coverslips were mounted on a microscope slide
and visualized with ﬂuorescence microscope (Carl Zeiss,
Germany). The images were captured and processed with
Metamorph software (Molecular Devices, CA, USA ).
2.12. Fusion of R-18-Labeled VLP with Jurkat Cells. The
fusion process was monitored by ﬂuorescence dequenching4 Journal of Biomedicine and Biotechnology
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Figure 1:ConstructionofpFastbacDualplasmid.ViralgeneswereﬂankedtwodiﬀerentrestrictionsiteswhilePCRampliﬁcationandligated
with pFastbac Dual vector as indicated. HA, M1 and M2, NA genes were paired and cloned in separate pFastbac Dual vectors and used for
bacmidsrecombination.WhenconstructingpFastbacDualvectorsforHA−andNA-EGFPVLPs,HAgenewasomitted,andNAwasreplaced
with NA-EGFP fusion gene, respectively. Tn7L and Tn7R were left and right arms of bacterial transposon Tn7 for gene recombination.
of R18 due to the lateral diﬀusion and dilution from viral to
cellular membrane as a result of membrane fusion [29, 30].
6 × 106 o fJ u r k a tc e l l sp r e t r e a t e dw i t h2 5m Mo fN H 4Cl at
37◦C for 15min were suspended in 500μl of PBS containing
25mM of NH4Cl and added 10μl of R18-labeled VLPs
(protein estimation 4.7μg) and then incubated at 37◦Cf o r
10min. The cells were sedimented by centrifugation at 4◦C
for 5min at 200×g and rapidly resuspended in 1ml of
PBS. Fusion of VLPs with plasma membrane was triggered
by lowering the pH to 5 with 0.25M of citric acid. The
maximum ﬂuorescence was obtained by lysing the viral
and cellular membrane with C12E8 at ﬁnal concentration of
3mM after each experiment. The ﬂuorescent increase was
detected by ﬂuorescence spectrophotometer F4500 (Hitachi)
withexcitationat540nmandemissionat578nm.Excitation
and emission slit widths were set at 2.5 and 10nm, respec-
tively. The ﬂuorescent images were captured by inverted
ﬂuorescence microscope (Aviovert, Carl Zeiss Inc.) with oil
immersionobjective(Plan-Apo40X,N.A.1.3)andprocessed
by MetaMorph software (Carl Zeiss Meditec, Gottingen,
Germany).
3. Results
3.1. Construction and Characterization of Inﬂuenza VLP from
Baculovirus/Sf9 Insect Cell Expression System. Figure 1 illus-
trates the construction of pFastbac Dual plasmids containing
inﬂuenza M1/HA, NA/M2, −/HA, and NA-EGFP/M2 gene
pairsfortheproductionofrecombinantbaculoviruses.Using
these recombinant baculoviruses, HA+VLPs, HA−VLPs, and
NA-EGFP VLP were generated. Figure 2 displays the Western
blot results (panel a) of the expressed proteins incorporated
in HA+ and HA−VLPs. The incorporated proteins were
expressed at similar level except for HA protein devoid
in HA−VLPs as expected. It is noted that the fraction of
cleavage for hemagglutinin in the present expression system
is estimated to be 33.7%. The morphology of the expressed
VLP as visualized by transmission electron microscopy
shown in Figure 2(b) is nearly spherical with a diameter of
∼100nm, close to the virus in the native context [31, 32].
The radius of VLP measured by light scattering was 63.3 ±
0.13nm with a convergent size distribution (Figure 2(c)).
3.2. Endocytosis of VLP in A549 Cells. Binding of hemag-
glutinins to cellular sialylated receptors initiates the host
endocytotic process for inﬂuenza virus entry [33–35]. Equal
amount of HA+VLP or HA−VLP, with regard to each
protein concentration, was added to A549 cells. Compared
to HA−VLP, HA-incorporated VLPs were signiﬁcantly endo-
cytosed by A549 cells. To conﬁrm that the endocytic process
is mediated by HA binding to the sialylated receptor, A549
cells were treated with neuraminidase from Vibrio cholerae.
After 2h of treatment, most of the sialic acids exposed on the
cell surface were removed as conﬁrmed by sialic acid-speciﬁc
lectin staining (see Figure S1 in Supplementary Material
available online at doi:10.11/2010/506363). As shown in
Figure 3, removal of sialic acids starkly decreased HA+VLP
engulfed by A549 cells. Also, attachment of VLP to another
s u s p e n d e dc e l ll i n eJ u r k a tc e l lc o u l db eh a m p e r e db yf e t u i n
(Figure 3(f)), which is a sialylated glycoprotein [36, 37]Journal of Biomedicine and Biotechnology 5
95
72
55
43
34
34
26
95
72
55
26
17
KDa
HA+ HA−
VLP
HA0
HA1
NA
M1
M2
1.4
1.2
1
0.8
0.6
0.4
0.2
0
100nm 200kV x40000
D
i
ﬀ
e
r
e
n
t
i
a
l
i
n
t
e
n
s
i
t
y
f
r
a
c
t
i
o
n
(
1
/
l
o
g
(
n
m
)
)
0.1 1 10 100 1000 10000 100000 1000000
Hydrodynamic radius (nm)
(a)
(b)
(c)
Figure 2: Characterization of insect cell-derived VLP. Equal amounts of VLP proteins were resolved by 12.5% discontinuous SDS
polyacrylamide gel and detected by four diﬀerent primary antibodies against HA, NA, M1, M2 (a). The morphology and particle size
distribution of HA+VLP were measured by transmission electron microscope (b) and dynamic light scattering (c), respectively.
and used as a model inhibitor for inﬂuenza virus infection
[38–41], in a dose-dependent manner. Taken together, the
HA+VLP was endocytosed by A549 cells through the binding
of viral HA and cellular sialylated receptor.
3.3. HA2 Exposure Recognized by Monoclonal Antibody IIF4
in Acidic Environment. I I F 4m A bh a sb e e nr e p o r t e dt ob e
speciﬁc to the epitope within HA2 aa 125–175 of the H3
subtype of inﬂuenza A virus and is well cross-reacting with
H4 and H5 viruses [42–44]. Previous studies demonstrated
that IIF4 epitopes on HA2 became accessible after acid
treatment on HA [42, 45]. The binding aﬃnity of HA2-
speciﬁc mAb IIF4 to HA+ VLPs at acidic pH was 0.18 ±
0.05nM, 32-fold higher than binding aﬃnity at neutral pH
(Figures 4(a) and 4(c) and Table 2). This implied that the
HA on VLP membrane could expose HA2 subunit leading
to fusion of the viral and cellular membranes as a result of
lowered pH.
To further support the SPR result that the HA+VLP has
much higher aﬃnity to IIF4 mAb at pH 5 than at pH 7.4,
immunoﬂuorescence staining was performed. As shown in
Figure 4(d) acidic buﬀer-treated HA+ VLP was recognizable
by HA2 IIF4 mAb whereas at natural pH HA+ VLP and
HA−VLP were not, in agreement with the SPR measurement
and indicating that the HA2 portion on the VLP is exposed
at acidic pH.
3.4. Fusion of Virus-Like Particles with Jurkat Cells. Flu-
orescent dequenching of R18 was employed to monitor
the fusion process of inﬂuenza virus with culture cells6 Journal of Biomedicine and Biotechnology
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Figure 3: HA-mediated endocytosis of VLP in A549 cells. A549 cells were added to VLPs labeled with DiO dye and incubated on ice for
1h. The unbound VLPs were washed away, and the cells were incubated at 37◦C for further 2h. (b) and (c) show A549 cells incubated with
HA− VLPs or HA+VLPs, respectively. (d) displays VCNA-pretreated A549 admixed HA+ VLP. (a) is a mock control. The upper and right
rectangular images of each panel depict horizontal and vertical cross-sections located at green and red lines, respectively. VLPs were labeled
with DiO dye (green), and A549 cells were stained with DiD dye (pink). Graph in (e) represents the average of endocytosed VLPs per cell.
Graph in (f) depicts the inhibitory eﬀect of fetuin on VLP binding. The values of relative VLP binding was determined by the ratio of R18
signals at each concentration of fetuin to the value obtained for the maximum binding of VLPs without the fetuin treatment.
Table 2: Binding aﬃnity of antibody to VLPs.
HA+VLP, pH7 HA+ VLP, pH5 HA−VLP, pH5
KD(n M) 5 .84 ±0.23 0.18 ±0.05 (n = 2) 6.28 ± 0.48 (n = 2)
[29, 30]. Thus R18-labeled VLPs were mixed with Jurkat
cells and collected by centrifugation of the cells. As shown in
Figure 5(a),H A + VLP could adhere to the cells surface and
form heterogeneous ﬂuorescent dots while HA− VLP could
be barely detected. After lowering the external pH of the
cells, the cell-bound VLPs underwent fusion with the cells, as
manifested by more homogenous dispersion of ﬂuorescent
signals around the cell. The fusion activity of HA+ VLP
was reaﬃrmed by the ﬂuorescence dequenching experiment
displayedinFigure 5(b)showingthatonlyHA+ VLPinduced
dramatic ﬂuorescence increase in response to acidic pH.
3.5. Anchorage of NA-EGFP on VLP as a Model for Antigen
Incorporation. Since the NA activity has been inferred
unnecessary for inﬂuenza VLP release from Sf9 insect cells
[46–49], the extracellular domain of NA was replaced with
the EGFP protein to demonstrate the possibility of accom-
modating other protein antigens on the VLP membrane
to extend the application of inﬂuenza VLP as an antigen
carrier. To construct the membrane-anchored chimera, the
amino terminal 61 amino acids of NA protein were retained
and fused with EGFP [50]. The NA-EGFP VLPs were
stained with lipophilic dye R18 to characterize the virus-likeJournal of Biomedicine and Biotechnology 7
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Figure 4: Conformational change of HA on VLPs triggered by low pH. The dissociation constant of mAb IIF4 with HA+ VLPs or HA− VLPs
at neutral or acidic pH was determined by SPR technique: (a) mAb IIF4 bound to HA+ VLPs at pH 7.4; (b) mAb IIF4 bound to HA+ VLPs
at pH 5.0; (c) mAb IIF4 bound to HA− VLPs at pH 5.0. (d) displays immunoﬂuorescence staining of VLP by mAb IIF4. See “Materials and
Methods” for details.
particles incorporated with EGFP. The ﬂuorescent images
shown in Figures 6(a)–6(c) were taken by reverse ﬂuorescent
microscope. Colocalization of NA-EGFP and R18 conﬁrms
that the virus-like particle was loaded with NA-EGFP.
To investigate the uptake of NA-EGFP-incorporated VLP
by cells, the VLPs were labeled with R18 and then admixed
with A549 cells at 4◦C to prevent pinocytosis. As shown in
Figures 6(d)–6(f),N A - E G F PV L Pc a nb et a k e nu pb yA 5 4 9
cells, and 20.6 ± 3.7% of the endocytotic vesicles contain the
EGFP ﬂuorescence.
4. Discussion
Using pFastbac Dual baculovirus transfer vector, we pro-
duced insect cell derived VLPs containing HA, M1, NA,
and M2 from inﬂuenza virus as well as EGFP-incorporated
VLPs. Despite the low NA content or deprived activity in the
EGFP-fused NA, the production of VLPs was not impaired.
It was reported that the proteins expressed in Sf9 insect
cells were devoid of sialylation as a result of the absence of
detectable sialyltransferase activities [46, 47] and CMP-sialic
acids [48, 49] and were N-glycosylated in high mannose type
[51]. It implies that VLP production in insect cells is viable
without the aid of NA activity for viral progeny release if HA
is incorporated. Also, N-glycans in high mannose type could
possibly enhance the HA binding to its sialylated receptors
[52] and facilitate the uptake of VLPs by APCs.
From a previous report, HA expression in insect cells
was retarded for posttranslational proteolysis[53]a sn o t e d
in our Western blot result. However, the proteolytic process
does not impair the binding capacity of HA but does
for membrane fusion [54], as demonstrated in our fusion
test (Figure 5). It is noted that some VLPs did not fuse
with the plasma membrane of the cells when pH was
lowered to 5 and clumped on the cell surface. It raises
an interesting question: since insect cell-derived VLP can8 Journal of Biomedicine and Biotechnology
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Figure 5: Membrane fusion of VLPs with Jurkat cells. Jurkat cells were mixed with R18-labeled VLPs for 10min and then collected for
detection of the membrane fusion. The fusion process was initiated by lowering the external pH to 5. (a) shows HA+ VLP binding, HA−
VLP binding, HA+ VLP bound to cells at pH5 for 2min, HA− VLP bound to cells at pH5 for 2min, from left to right. Graph in (b) depicts
the time proﬁle of VLP fusion with plasma membrane triggered by acidiﬁcation at 1min as indicated. The autoﬂuorescence of Jurkat cells
obtained as a control was subtracted from the intensity value.
induce cell-mediated immune response [10–12], how are the
HA proteins anchored on the late endosomal membrane as
a result of HA-induced membrane fusion or accumulated
in the endosome lumen involved in cross presentation to
MHC I molecules, leading to HA-speciﬁc CTL induction?
To address this question, mammalian cell-derived inﬂuenza
VLP with or without proteolytic site in HA protein could be
tested for HA-speciﬁc CTL induction, protein processing as
well as MHC I loading.
T h es i z eo fe x p r e s s e dV L Pi se s t i m a t e dt ob e∼100nm
while the average size deduced from dynamic light scattering
is ∼120nm. The discrepancy between the two data can be
at least partly accounted for by the fact that the latter reports
thehydrodynamicdiameteroftheparticle,namely,including
the hydrated water molecules surrounding the VLP, thus the
larger size [31].
Low pH-triggered conformational change can be
detected by mAb IIF4 with the epitope within HA2 125-175,
whichwasexposeduponloweringpHto5.0asdeducedfrom
33-fold increase in binding aﬃnity to IIF4 when switched to
acidic pH. Again, this reaﬃrms that the constructed VLP can
be used as a valid mimic to the native virus for the functional
and structural study of hemagglutinin.
Further investigation of the biological activity for the
synthesized VLP was performed on fusion to the Jurkat
cell membrane induced by HA (Figure 5)a sp r o b e db y
dequenching of the embedded R18 label due to its dilution
arising from membrane merger. The result established the
f u n c t i o ne x e r t e db yH Aa sH A −VLP did not exhibit fusion
activity.BymeasuringtheﬂuorescenceintensityofR18,IC50
of fetuin on binding inhibition of HA+VLP to Jurkat cell was
estimated to be 147μM (7.1mg/ml), compared to a previousJournal of Biomedicine and Biotechnology 9
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Figure 6: Endocytosis of NA-EGFP incorporated VLP in A549 cells. The NA-EGFP VLPs were stained with R18 dye. Panels (a) and (b) show
theEGFPandR18signals,respectively.Panelcdisplaysthesuperimposedimagesofpanels(a)and(b).Panel(e)illustratestheendocytosisof
NA-EGFP VLP in A549 cells with panel (d) as a mock control. The upper and right rectangular images of panel (d) and (e) depict horizontal
and vertical cross-sections located at green and red lines, respectively. Rectangular images of a and d show the EGFP signals (green) whereas
those of b and c show the R18 signals (red). The A549 cells were stained with DiD dye (pink). Graph (f) displays the average number of
endocytosed vesicles containing NA-EGFP VLP per cell.
result of 6.4mg/ml for inhibition of viral infection by focus-
forming assays [40]. Based on viral binding and fusion both
experimentscanbeusedasscreeningplatformsforinhibitors
targeting viral entry.
The ﬂuorescent intensity of EGFP was shown to be
inﬂuenced by the surrounding pH [55]. That could beget the
low percentage of engulfed vesicles containing EGFP signal.
However, it reinforced that the application NA chimera for
antigen incorporation in VLP was feasible. Moreover, EGFP
wasreportedasanoninvasiveintracellularpHindicator[56].
The EGFP-VLP could be expanded for its utility as a reporter
tag, particularly as a pH sensor inside the HA-targeted cells.
FurtherstudyonthetimevariationofEGFPintheendosome
can be conducted to monitor the time course of the fusion
process and traﬃcking of VLP within the cell, which may
provide insight into the antigen presentation of the virus and
the dynamics and the route of virus invasion in the cell.
5. Conclusions
The extensive biophysical characterization of inﬂuenza VLP
containing M1, HA, NA, and M2 viral structural proteins
establishedareliableprotocolofsynthesizingalargequantity
of the virus mimetic for use in vaccine study, in particular
for the HA as the major antigen. The incorporation of a
ﬂuorescent label demonstrates the feasible use of VLP as
an antigen carrier as well as a possible tool for microscopic
observation of the virus dynamics and interaction with the
cellular components within the cell.
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